GLP-1 agonists are widely used in the treatment of T2DM and have significant therapeutic effects on patients with hyperglycemia, insulin resistance, and β cell dysfunction (Lee et al., 2018). The gene discussed is GCG; the disease is type 2 diabetes mellitus.